TB-500 is a synthetic form of thymosin beta-4 (TB4), which is a peptide that naturally occurs in the body. TB4 is implicated in biological processes such as wound healing, angiogenesis, cell migration, cell proliferation, cell migration, down-regulation of inflammation, and re-epithelialization (1).
TB-500 is an acetylated form of seven peptides from the active site of TB4. The acetylation adds an acetyl group to the peptide, therefore modifying the peptide’s biological properties. However, it is not clear if the acetylation in TB-500 has an impact on the peptide’s ability to bind actin, heal wounds, repair skin, or induce angiogenesis (1).
Most of the available scientific literature is focused on TB4 and not T-500. There is some evidence that TB4 can promote wound healing via promoting angiogenesis. Angiogenesis is an essential process in repair post-injury, as it involves stimulation of new blood vessel formation. A study found that administration of topical TB4 increased re-epithelialization by 42 percent versus saline controls. Additionally, treated wounds demonstrated increased collagen deposition and angiogenesis (2).
Another study in animals shows that TB4 could play a role in cardiac repair after myocardial infarction. One study found that TB4 has potential to inhibit myocardial cell death, activate new vessel growth, and stimulate endogenous cardiac progenitors. By stimulating myocardial and vascular regeneration, TB4 could help improve heart function post-injury (3).
Clinical studies are a bit more limited versus data available in preclinical animal models. However, two phase II clinical trials in pressure ulcers and stasis showed that TB4 was associated with faster healing. Patients with TB4 had healing time decrease by as much as a month versus those that did not take TB4 (4).
The most important takeaway from available data is that most of the evidence comes from TB4, not TB-500. Although the two are similar, they are not the same as TB4 is a full-length amino acid containing 43 amino acids, while TB-500 is only a short fragment of seven amino acids. Thus the results cannot necessarily be extrapolated, and data is still somewhat limited with TB4.
TB-500 is not approved by the US Food and Drug Administration (FDA), nor is its counterpart TB4. Thus, its safety and efficacy has not been evaluated enough to establish its potential in the clinical setting.
Currently TB-500 is only available as a research chemical. Because it is not regulated by the FDA, it carries similar concerns to other peptides like potentials for contamination and mislabeling.
As most research has been done with TB4, the majority of safety data has been extrapolated from TB4 research. The safety profile, including potential side effects, of TB-500 is thus not well-characterized and little is known about its risks. However, some evidence suggests that due to TB4s ability to promote cell migration and angiogenesis, it could stimulate tumor metastasis (5).
In summary, the efficacy and risk profile of TB-500 is not well known given the absence of human clinical data. Additionally, it has contamination risks given that it is not a regulated product.
The information provided in this article is for educational purposes only and is not intended as medical advice. Many peptides are not FDA-approved for human use outside of limited clinical contexts. These compounds are often obtained through unregulated sources that lack quality control. Studies suggest 30–65% of products may be contaminated or mislabeled, with risks including endotoxins, heavy metals, and incorrect sequences. At Weight Loss & Vitality, we focus on evidence-based, medically supervised therapies.
As of April 21, 2026, regulatory status for many peptides remains under review and may change as additional data and guidance become available.
The science behind peptides continues to evolve, highlighting the need for responsible and informed use. At Weight Loss & Vitality, our peptide therapy programs are grounded in clinical experience and evidence-based care.
References
